Remicade C1q Binding Assays

BioOutsource offers off-the-shelf Remicade C1q binding assays to support Remicade biosimilar manufacture, process development, characterization and biosimilarity studies. We offer industry leading Remicade comparability and Remicade characterization services and these can be adapted for your product where necessary.

The complement system complements the ability of antibodies to clear pathogens and cancerous cells from the body. It is a collection of small proteins present in the blood that typically circulate as inactive precursors. The classical pathway is triggered by activation of the C1-complex which is composed of a single C1q molecule with 2 molecules of C1r and C1s, and occurs when C1q binds multiple IgG molecules complexed with antigen; this can lead to a signalling cascade culminating in complement-dependent cytotoxicity (CDC). Remicade (infliximab) mediates its activity through the interaction with the TNF-Alpha and, following binding to the membrane bound form, Remicade is capable of activating the complement cascade and inducing cell lysis via Complement Dependent Cytotoxicity. Activation of complement is experimentally determined using the C1q binding assay.